A critical role for IFN regulatory factor 1 in NKT cell-mediated liver injury induced by α-galactosylceramide

Journal of Immunology

Volumn 185, Issue 4, 2010, Pages 2536-2543

  Cao, Zongxian ^a   Dhupar, Rajeev ^a   Cai, Changchun ^a   Li, Peiyuan ^a   Billiar, Timothy R ^a   Geller, David A ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GAMMA INTERFERON; INTERFERON REGULATORY FACTOR 1; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA; ALPHA-GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; LIVER; LIVER CELL; LIVER INJURY; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; ANIMAL; C57BL MOUSE; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; GENE INACTIVATION; GENETICS; IMMUNOLOGY; LIVER DISEASE; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; GENE EXPRESSION; GENE KNOCKOUT TECHNIQUES; HEPATOCYTES; INTERFERON REGULATORY FACTOR-1; INTERFERON-GAMMA; LIVER; LIVER DISEASES; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; NITRIC OXIDE SYNTHASE TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956921833     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000092     Document Type: Article

References (41)

1. Zhai, Y., B. Qiao, F. Gao, X. Shen, A. Vardanian, R. W. Busuttil, and J. W. Kupiec-Weglinski. 2008. Type I, but not type II, interferon is critical in liver injury induced after ischemia and reperfusion. Hepatology 47: 199-206.
2. Burt, B. M., G. Plitas, J. A. Stableford, H. M. Nguyen, Z. M. Bamboat, V. G. Pillarisetty, and R. P. DeMatteo. 2008. CD11c identifies a subset of murine liver natural killer cells that responds to adenoviral hepatitis. J. Leukoc. Biol. 84: 1039-1046.
3. Zhai, Y., X. D. Shen, R. O'Connell, F. Gao, C. Lassman, R. W. Busuttil, G. Cheng, and J. W. Kupiec-Weglinski. 2004. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent MyD88-independent pathway. J. Immunol. 173: 7115-7119.
4. Kan,W. H., J. T. Hsu,M. G. Schwacha, M. A. Choudhry, R. Raju, K. I. Bland, and I. H. Chaudry. 2008. Selective inhibition of iNOS attenuates trauma-hemorrhage/resuscitation-induced hepatic injury. J. Appl. Physiol. 105: 1076-1082.
5. Kingham, T. P., U. I. Chaudhry, G. Plitas, S. C. Katz, J. Raab, and R. P. DeMatteo. 2007. Murine liver plasmacytoid dendritic cells become potent immunostimulatory cells after Flt-3 ligand expansion. Hepatology 45: 445-454.
6. Hsieh, C. H., M. Frink, Y. C. Hsieh, W. H. Kan, J. T. Hsu, M. G. Schwacha, M. A. Choudhry, and I. H. Chaudry. 2008. The role of MIP-1α in the development of systemic inflammatory response and organ injury following trauma hemorrhage. J. Immunol. 181: 2806-2812.
7. Van Kaer, L. 2005. α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles. Nat. Rev. Immunol. 5: 31-42.
8. Godfrey, D. I., and M. Kronenberg. 2004. Going both ways: immune regulation via CD1d-dependent NKT cells. J. Clin. Invest. 114: 1379-1388.
9. Bendelac, A., P. B. Savage, and L. Teyton. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25: 297-336.
10. Kita, H., O. V. Naidenko, M. Kronenberg, A. A. Ansari, P. Rogers, X. S. He, F. Koning, T. Mikayama, J. Van DeWater, R. L. Coppel, et al. 2002. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology 123: 1031-1043.
11. Minagawa, M., Q. Deng, Z. X. Liu, H. Tsukamoto, and G. Dennert. 2004. Activated natural killer T cells induce liver injury by Fas and tumor necrosis factor-α during alcohol consumption. Gastroenterology 126: 1387-1399.
12. Shimamura, K., H. Kawamura, T. Nagura, T. Kato, T. Naito, H. Kameyama, K. Hatakeyama, and T. Abo. 2005. Association of NKT cells and granulocytes with liver injury after reperfusion of the portal vein. Cell. Immunol. 234: 31-38.
13. Lappas, C. M., Y. J. Day, M. A. Marshall, V. H. Engelhard, and J. Linden. 2006. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J. Exp. Med. 203: 2639-2648.
14. Ajuebor, M. N. 2007. Role of NKT cells in the digestive system. I. Invariant NKT cells and liver diseases: is there strength in numbers? Am. J. Physiol. 293: G651-G656.
15. + T (NKT) cells in the spontaneous acceptance of rat liver allografts. Transplantation 80: 1749-1755.
16. α14 NKT cells by glycosylceramides. Science 278: 1626-1629.
17. Biburger, M., and G. Tiegs. 2005. α-Galactosylceramide-induced liver injury in mice is mediated by TNF-α but independent of Kupffer cells. J. Immunol. 175: 1540-1550. (Pubitemid 41023055)
18. Osman, Y., T. Kawamura, T. Naito, K. Takeda, L. Van Kaer, K. Okumura, and T. Abo. 2000. Activation of hepatic NKT cells and subsequent liver injury following administration of α-galactosylceramide. Eur. J. Immunol. 30: 1919-1928.
19. Fujii, H., S. Seki, S. Kobayashi, T. Kitada, N. Kawakita, K. Adachi, H. Tsutsui, K. Nakanishi, H. Fujiwara, Y. Ikarashi, et al. 2005. A murine model of NKT cellmediated liver injury induced by α-galactosylceramide/D- galactosamine. Virchows Arch. 446: 663-673.
20. Nakagawa, R., I. Nagafune, Y. Tazunoki, H. Ehara, H. Tomura, R. Iijima, K. Motoki, M. Kamishohara, and S. Seki. 2001. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α- galactosylceramide in mice. J. Immunol. 166: 6578-6584. (Pubitemid 32467197)
21. Inui, T., H. Nakashima, Y. Habu, R. Nakagawa, M. Fukasawa, M. Kinoshita, N. Shinomiya, and S. Seki. 2005. Neutralization of tumor necrosis factor abrogates hepatic failure induced by α-galactosylceramide without attenuating its antitumor effect in aged mice. J. Hepatol. 43: 670-678. (Pubitemid 41253235)
22. Kröger, A., M. Köster, K. Schroeder, H. Hauser, and P. P. Mueller. 2002. Activities of IRF-1. J. Interferon Cytokine Res. 22: 5-14.
23. Honda, K., A. Takaoka, and T. Taniguchi. 2006. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 25: 349-360.
24. Taniguchi, T., K. Ogasawara, A. Takaoka, and N. Tanaka. 2001. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19: 623-655.
25. Geller, D. A., D. Nguyen, R. A. Shapiro, A. Nussler, M. Di Silvio, P. Freeswick, S. C. Wang, D. J. Tweardy, R. L. Simmons, and T. R. Billiar. 1993. Cytokine induction of interferon regulatory factor-1 in hepatocytes. Surgery 114: 235-242.
26. Tsung, A., M. T. Stang, A. Ikeda, N. D. Critchlow, K. Izuishi, A. Nakao, M. H. Chan, G. Jeyabalan, J. H. Yim, and D. A. Geller. 2006. The transcription factor interferon regulatory factor-1 mediates liver damage during ischemiareperfusion injury. Am. J. Physiol. 290: G1261-G1268.
27. Kim, K. H., R. Dhupar, S. Ueki, J. Cardinal, P. Pan, Z. Cao, S. W. Cho, N. Murase, A. Tsung, and D. A. Geller. 2009. Donor graft interferon regulatory factor-1 gene transfer worsens liver transplant ischemia/reperfusion injury. Surgery 146: 181-189.
28. Ueki, S., R. Dhupar, J. Cardinal, A. Tsung, J. Yoshida, K. S. Ozaki, J. R. Klune, N. Murase, and D. A. Geller. 2010. Critical role of interferon regulatory factor-1 in murine liver transplant ischemia reperfusion injury. Hepatology 51: 1692-1701.
29. Cao, Z., J. Fang, C. Xia, X. Shi, and B. H. Jiang. 2004. trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1α and vascular endothelial growth factor expression in human ovarian cancer cells. Clin. Cancer Res. 10: 5253-5263.
30. Cao, Z., Y. Yuan, G. Jeyabalan, Q. Du, A. Tsung, D. A. Geller, and T. R. Billiar. 2009. Preactivation of NKT cells with α-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor. Am. J. Physiol. 297: G249-G258.
31. Taki, S., T. Sato, K. Ogasawara, T. Fukuda, M. Sato, S. Hida, G. Suzuki, M. Mitsuyama, E. H. Shin, S. Kojima, et al. 1997. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity 6: 673-679. (Pubitemid 27305730)
32. Kamijo, R., H. Harada, T. Matsuyama, M. Bosland, J. Gerecitano, D. Shapiro, J. Le, S. I. Koh, T. Kimura, S. J. Green, et al. 1994. Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 263: 1612-1615. (Pubitemid 24128365)
33. Martin, E., C. Nathan, and Q. W. Xie. 1994. Role of interferon regulatory factor 1 in induction of nitric oxide synthase. J. Exp. Med. 180: 977-984.
34. Chen, T., R. Zamora, B. Zuckerbraun, and T. R. Billiar. 2003. Role of nitric oxide in liver injury. Curr. Mol. Med. 3: 519-526.
35. Lee, V. G., M. L. Johnson, J. Baust, V. E. Laubach, S. C. Watkins, and T. R. Billiar. 2001. The roles of iNOS in liver ischemia-reperfusion injury. Shock 16: 355-360.
36. Crispe, I. N. 2009. The liver as a lymphoid organ. Annu. Rev. Immunol. 27: 147-163.
37. Knolle, P. A., and G. Gerken. 2000. Local control of the immune response in the liver. Immunol. Rev. 174: 21-34.
38. Watanabe, N., J. Sakakibara, A. G. Hovanessian, T. Taniguchi, and T. Fujita. 1991. Activation of IFN-β element by IRF-1 requires a posttranslational event in addition to IRF-1 synthesis. Nucleic Acids Res. 19: 4421-4428.
39. Ogasawara, K., S. Hida, N. Azimi, Y. Tagaya, T. Sato, T. Yokochi-Fukuda, T. A. Waldmann, T. Taniguchi, and S. Taki. 1998. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature 391: 700-703. (Pubitemid 28113217)
40. + T) cells, natural killer cells, and intestinal intraepithelial T cells. J. Exp. Med. 187: 967-972.
41. Jukes, J. P., K. J. Wood, and N. D. Jones. 2007. Natural killer T cells: a bridge to tolerance or a pathway to rejection? Transplantation 84: 679-681.